STOCK TITAN

Voyager Therapeutics Inc - VYGR STOCK NEWS

Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.

Overview

Voyager Therapeutics Inc (VYGR) is a biotechnology company focused on developing innovative gene therapies for severe and debilitating diseases of the central nervous system (CNS). Using advanced AAV gene therapy techniques and its proprietary TRACER™ capsid discovery platform, Voyager is dedicated to overcoming traditional barriers in gene delivery and creating transformative solutions for neurological disorders.

Core Technology and Platform

The company leverages its TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform to engineer and optimize novel AAV capsids that are designed to cross the blood-brain barrier with high efficiency. This RNA-based screening enables rapid identification of capsid variants with enhanced CNS tropism and controlled tissue targeting, ensuring robust genetic payload delivery to areas of the brain traditionally hard to reach. The platform underpins both its gene therapy and antibody development programs, reflecting a robust integration of genetic science and neuroscience.

Pipeline and Disease Focus

Voyager Therapeutics maintains an extensive pipeline of programs aimed at addressing several critical CNS diseases. The company is developing gene therapy candidates to target conditions such as Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Additionally, Voyager is advancing therapies aimed at modifying the pathological processes in Alzheimer’s disease through tau silencing and anti-tau antibodies. Each candidate is carefully designed to modulate protein expression in the CNS, aiming to slow disease progression and improve patient outcomes.

Research and Development Approach

Emphasizing rigorous process development and production scalability, Voyager invests heavily in vector optimization and sophisticated dosing techniques. The company conducts cross-species preclinical studies to ensure that its TRACER-generated capsids achieve widespread and efficient gene expression while minimizing off-target effects. Its commitment to scientific excellence is reflected in its strategic external collaborations, which not only validate its technology but also extend its reach within the neurogenetic medicines field.

Industry Significance and Competitive Position

Voyager Therapeutics distinguishes itself within the biotechnology landscape through its specialized focus on CNS diseases and its innovative AAV-based gene therapy solutions. By integrating cutting-edge gene editing methodologies with deep neuroscientific insights, the company fills a significant unmet need in neurological drug development. Its collaboration with established industry partners further underscores the scientific reliability, stringent development standards, and translational potential of its candidates. The company’s balanced portfolio and technology-driven approach position it as a critical contributor to the evolution of gene therapies for challenging neurological conditions.

Commitment to Innovation and Patient Impact

At the heart of Voyager Therapeutics’ mission is the goal of modifying the course of devastating neurological diseases. By focusing on durable gene expression attainable through a single administration, the company aims to provide long-lasting therapeutic benefits that can transform the quality of life for patients. Its efforts in process development and clinical standardization continue to set benchmarks within the field, reflecting a commitment to excellence that is both scientifically robust and patient-centered.

This comprehensive approach—encompassing advanced vector engineering, strategic collaborations, and meticulous clinical development—underscores Voyager Therapeutics’ prominence in the realm of neurogenetic medicines and offers a detailed perspective for investors and industry observers alike.

Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced the appointment of Alfred W. Sandrock, Jr. to its Board of Directors and the promotion of Robin Swartz to Chief Operating Officer, effective February 7, 2022. Dr. Sandrock, a seasoned drug developer with extensive experience at Biogen, will help steer Voyager's strategies for its TRACER™ AAV capsid screening platform and foster collaborations. Ms. Swartz will oversee several operational departments, marking a strategic leadership change aimed at enhancing the company's gene therapy initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
management
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) has presented preclinical data showing that its proprietary AAV vector, developed using TRACER™ technology, effectively targets HER2+ breast cancer brain metastases. The findings indicate that intravenous dosing of this vector leads to significant tumor reduction and improved survival rates in mouse models. The anti-HER2 antibody produced through this method achieves high concentrations in cerebrospinal fluid, suggesting potential for effective treatment against CNS tumors. Voyager plans to continue optimizing this innovative gene therapy approach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced the presentation of preclinical data from its vectorized antibody program at the 26th Annual Society for Neuro-Oncology Meeting on Nov. 19, 2021. The presentation, titled AAV mediated brain delivery of an ADCC-enhanced antibody obviates xenograft growth in mouse models of HER2+ breast cancer brain metastasis, will be delivered by Dan R. Laks, Ph.D., at 4:15 p.m. ET. This represents a significant advancement in the development of AAV gene therapy technology, aiming to treat severe diseases through innovative approaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
conferences clinical trial
Rhea-AI Summary

Voyager Therapeutics has partnered with Pfizer through a licensing agreement to access its TRACER™ capsids for gene therapies targeting neurological and cardiovascular diseases. The deal includes a $30M upfront payment and potential milestone payments of up to $600M. Preclinical results from Voyager's GBA1 gene therapy indicate significant CNS distribution and enzyme activity correction. For Q3 2021, Voyager reported a net loss of $25.1M, down from a net income of $85.6M in Q3 2020, with collaboration revenue decreasing from $117.8M to $1.5M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
none
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced promising preclinical data on its GBA1 gene replacement therapy, showing sustained correction of GCase enzyme activity across multiple brain regions in mice after a single intravenous dose. Results from the virtual Congress of the European Society of Gene and Cell Therapy indicated a 300% to 660% increase in GCase levels, potentially enabling effective treatment for neurological diseases like Gaucher disease and Parkinson’s. The therapy was well-tolerated, showcasing the advantages of blood-brain barrier-penetrant AAV capsids over traditional delivery methods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) has entered a partnership with Pfizer, receiving $30 million upfront. The collaboration allows Pfizer to access Voyager's advanced AAV capsids, enhancing drug delivery for gene therapies targeting neurological and cardiovascular diseases. The agreement includes potential exercise fees and milestone payments up to $600 million, along with royalties based on product sales. Voyager retains rights for other applications of its TRACER technology, expected to boost the development of gene therapies and address unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
56.68%
Tags
none
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced its participation in three upcoming virtual investor conferences on September 9, 14, and 15, 2021. These conferences will feature a fireside chat at the Wells Fargo Securities Healthcare Conference, a fireside chat at the Morgan Stanley Global Healthcare Conference, and a company presentation at the Baird Global Healthcare Conference, respectively. Investors can access these sessions via the Investors & Media section of Voyager's website, where replays will also be archived for at least 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
conferences
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced its participation in two upcoming virtual investor conferences. The first is the Wedbush PacGrow Healthcare Conference, featuring a panel discussion on August 11, 2021, at 8:35 AM ET. The second is the Canaccord Genuity Growth Conference, which includes a fireside chat on August 12, 2021, from 10:30 to 10:55 AM ET. Investors can access these sessions via the Investors & Media section of Voyager’s website. The company focuses on advancing AAV gene therapy to treat serious diseases using its TRACER™ screening platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
conferences
-
Rhea-AI Summary

Voyager Therapeutics (VYGR) announced significant updates in its pipeline, focusing on second-generation programs for Huntington’s disease, ALS, spinal muscular atrophy, and GBA1 mutation-related diseases, utilizing proprietary AAV capsids. The TRACER platform aims to discover targeted AAV capsids for various tissues. Financially, collaboration revenue dropped to $1.4 million in Q2 2021 from $28.7 million in Q2 2020, while net loss increased to $30.1 million. The company maintains a cash position of $143 million, sufficient for operations into early 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.04%
Tags
none
Rhea-AI Summary

Voyager Therapeutics (NASDAQ: VYGR) announces a strategic shift towards enhancing its gene therapy pipeline, particularly focusing on VY-HTT01 for Huntington's disease. Michael Higgins steps in as interim CEO following Andre Turenne's resignation, while Glenn Pierce assumes the role of interim CSO. The company aims to maximize its TRACER gene therapy platform, which has shown promising transgene expression in non-human primates. Upcoming milestones include the initiation of a Phase 1/2 clinical trial for VY-HTT01 in Q4 2021, emphasizing the potential of its next-generation AAV capsids.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.25%
Tags
management

FAQ

What is the current stock price of Voyager Therapeutics (VYGR)?

The current stock price of Voyager Therapeutics (VYGR) is $3.37 as of April 1, 2025.

What is the market cap of Voyager Therapeutics (VYGR)?

The market cap of Voyager Therapeutics (VYGR) is approximately 185.2M.

What is the primary focus of Voyager Therapeutics?

Voyager Therapeutics is dedicated to developing gene therapies for severe neurological diseases using innovative AAV platforms and advanced vector engineering.

What is the TRACER™ platform?

The TRACER™ platform is an RNA-based screening technology that enables rapid discovery and optimization of AAV capsids for improved blood-brain barrier penetration and targeted CNS delivery.

Which central nervous system diseases does Voyager address?

Voyager’s pipeline includes therapies for Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, and Alzheimer’s disease, among other CNS conditions.

How does Voyager’s technology enhance gene delivery to the brain?

Their engineered AAV capsids are designed to cross the blood-brain barrier efficiently, target specific cell types, and achieve robust gene expression while limiting off-target transduction.

What distinguishes Voyager Therapeutics from other biotech companies?

Voyager is distinguished by its specialized focus on CNS diseases, its proprietary TRACER™ capsid discovery platform, and its commitment to integrating advanced gene therapy approaches with deep neuroscientific expertise.

Does Voyager collaborate with other organizations?

Yes, Voyager has strategic collaborations with established biotech firms, enhancing the scientific rigor and translational impact of its gene therapy candidates.

How do Voyager's therapies aim to impact patient treatment?

Their gene therapy candidates are designed to modify the underlying disease mechanisms by regulating protein expression, potentially slowing disease progression and improving patient quality of life.

What research methods support Voyager's development approach?

Voyager employs cross-species preclinical studies, advanced vector optimization, and robust process development to validate the safety and efficacy of its therapies.
Voyager Therapeutics Inc

Nasdaq:VYGR

VYGR Rankings

VYGR Stock Data

185.22M
45.58M
17%
63.9%
4.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
LEXINGTON